Mirum Pharmaceuticals (NASDAQ:MIRM) Raised to Hold at Wall Street Zen

Mirum Pharmaceuticals (NASDAQ:MIRM) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Other analysts have also issued reports about the company. CLSA set a $146.00 price target on Mirum Pharmaceuticals in a research note on Monday, June 15th. Citizens Jmp dropped their price objective on shares of Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating for the company in a research note on Thursday. Morgan Stanley set a $137.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday. Royal Bank Of Canada decreased their target price on shares of Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, JPMorgan Chase & Co. boosted their target price on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.33.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $100.65 on Friday. Mirum Pharmaceuticals has a fifty-two week low of $57.79 and a fifty-two week high of $130.00. The firm has a market cap of $6.54 billion, a PE ratio of -6.92 and a beta of 0.52. The business’s fifty day moving average is $110.33 and its two-hundred day moving average is $101.86. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The business had revenue of $176.24 million during the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. Mirum Pharmaceuticals’s revenue for the quarter was up 37.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) EPS. Analysts anticipate that Mirum Pharmaceuticals will post -4.42 earnings per share for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 20,000 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $122.27, for a total transaction of $2,445,400.00. Following the completion of the sale, the chief executive officer owned 194,309 shares of the company’s stock, valued at approximately $23,758,161.43. The trade was a 9.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 1,840 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $105.29, for a total value of $193,733.60. Following the sale, the senior vice president owned 1,274 shares of the company’s stock, valued at $134,139.46. This represents a 59.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 67,155 shares of company stock valued at $7,185,662. Company insiders own 8.32% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of MIRM. Comerica Bank raised its holdings in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period. AQR Capital Management LLC grew its stake in Mirum Pharmaceuticals by 307.3% during the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after buying an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Mirum Pharmaceuticals by 7.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after buying an additional 1,720 shares during the period. Caxton Associates LLP acquired a new stake in shares of Mirum Pharmaceuticals in the first quarter worth $217,000. Finally, Empowered Funds LLC increased its position in shares of Mirum Pharmaceuticals by 15.4% in the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after acquiring an additional 5,120 shares in the last quarter.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue reached $176.24 million, beating the $166.33 million consensus estimate and rising 37.9% year over year. Growth was driven by Livmarli and Mirum’s other bile-acid therapies. Management also raised its 2026 sales outlook, providing a favorable signal about demand and the company’s commercial trajectory. Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts remain broadly constructive despite reducing their targets. TD Cowen lowered its target to $140 and retained a “buy” rating; Citizens JMP cut its target to $137 but maintained “market outperform”; and HC Wainwright reduced its target to $140 while keeping a “buy” rating. These targets imply substantial potential upside from recent trading levels.
• Neutral Sentiment: Mirum reported a quarterly loss of $1.06 per share, wider than the $0.74 consensus loss and the $0.12 loss recorded a year earlier. The loss reflects continued investment in the company’s rare-disease pipeline, but it remains a near-term valuation concern. Mirum’s Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
• Negative Sentiment: Citizens warned that an “unexpected” FDA request for a Phase 3 study clouds Mirum’s near-term outlook. The additional regulatory requirement could delay development or approval plans, increase spending, and weigh on investor sentiment.
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734, reducing her direct holdings by 59.1%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which lessens its signaling value, but the sale still adds a modest negative headline.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.